» Articles » PMID: 16614742

The Natural History of Hepatitis C Virus (HCV) Infection

Overview
Journal Int J Med Sci
Specialty General Medicine
Date 2006 Apr 15
PMID 16614742
Citations 282
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, as well as the most common indication for liver transplantation in many countries. Although the incidence of hepatitis C infection has dramatically decreased during the past decade, the worldwide reservoir of chronically infected persons is estimated at 170 million, or 3% of the global population. There is much controversy surrounding the natural history of hepatitis C infection. The rate of chronic HCV infection is affected by a person's age, gender, race, and viral immune response. Approximately 75%-85% of HCV-infected persons will progress to chronic HCV infection, and are at risk for the development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma (HCC). The rate of progression to cirrhosis is highly variable, and is influenced by several factors, including the amount of alcohol consumption, age of initial HCV infection, degree of inflammation and fibrosis on liver biopsy, HIV and HBV coinfection, and comordid conditions. An estimated 10%-15% of HCV-infected persons will advance to cirrhosis within the first 20 years. Persons with cirrhosis are at increased risk of developing HCC. An understanding of the natural history of hepatitis C is essential to effectively manage, treat, and counsel individuals with HCV infection.

Citing Articles

Outcomes of Low Barrier Hepatitis C Treatment in High Risk Populations From Primary Care.

Austin S, Seemiller K, Nolton B, Hobart E, Ling B, Ghobrial J J Community Hosp Intern Med Perspect. 2025; 14(6):10-17.

PMID: 39839167 PMC: 11745185. DOI: 10.55729/2000-9666.1404.


Role of CALCR expression in liver cancer: Implications for the immunotherapy response.

Wang S, Wang W, Zeng J Mol Med Rep. 2024; 31(2).

PMID: 39611512 PMC: 11622006. DOI: 10.3892/mmr.2024.13406.


Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey.

Kassa G, Weldemariam A, Abrahim S, French C, Wolday D, Dagne E J Viral Hepat. 2024; 32(4):e14037.

PMID: 39569765 PMC: 11883455. DOI: 10.1111/jvh.14037.


Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis.

Farrag A, Kamel A Virol J. 2024; 21(1):275.

PMID: 39497140 PMC: 11533316. DOI: 10.1186/s12985-024-02544-2.


Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis.

Sinclair 3rd S, Shearen S, Ghobrial Y, Trad G, Abdul Basit S, Shih D Viruses. 2024; 16(10).

PMID: 39459866 PMC: 11512229. DOI: 10.3390/v16101531.


References
1.
Wiley T, Breidi L, McCarthy M, Layden T . Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998; 28(3):805-9. DOI: 10.1002/hep.510280330. View

2.
Sasaki N, Matsui A, Momoi M, Tsuda F, Okamoto H . Loss of circulating hepatitis C virus in children who developed a persistent carrier state after mother-to-baby transmission. Pediatr Res. 1997; 42(3):263-7. DOI: 10.1203/00006450-199709000-00003. View

3.
. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet. 1999; 351(9115):1535-9. View

4.
Neumann A, Lam N, Dahari H, Gretch D, Wiley T, Layden T . Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998; 282(5386):103-7. DOI: 10.1126/science.282.5386.103. View

5.
Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-62. DOI: 10.1126/science.2523562. View